tetano
Editor, Senior Moderator
Nat Biomed Eng
. 2020 Oct 29.
doi: 10.1038/s41551-020-00642-4. Online ahead of print.
Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates
Tiancheng Liu[SUP] 1 [/SUP], Jessica Hsiung[SUP] 1 [/SUP], Su Zhao[SUP] 1 [/SUP], Jessica Kost[SUP] 1 [/SUP], Deepika Sreedhar[SUP] 1 [/SUP], Carl V Hanson[SUP] 2 [/SUP], Kjerstie Olson[SUP] 3 [/SUP], Douglas Keare[SUP] 1 [/SUP], Shin Ting Chang[SUP] 1 [/SUP], Kevin P Bliden[SUP] 4 [/SUP], Paul A Gurbel[SUP] 4 [/SUP], Udaya S Tantry[SUP] 4 [/SUP], John Roche[SUP] 1 [/SUP], Cynthia Press[SUP] 3 [/SUP], John Boggs[SUP] 3 [/SUP], Jorge P Rodriguez-Soto[SUP] 3 [/SUP], Jose G Montoya[SUP] 5 [/SUP], Meijie Tang[SUP] 6 [/SUP], Hongjie Dai[SUP] 7 [/SUP]
Affiliations
Abstract
Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are essential for the control of the COVID-19 (coronavirus disease 2019) pandemic. Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobulin avidities against coronavirus antigens from SARS-CoV-2, SARS-CoV-1 and the common-cold viruses OC43, HKU1, NL63 and 229E. The antibody assay detected immunoglobulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the pandemic, including 73 that were positive for other viruses). We used the antibody-avidity assay to study antibody-maturation patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.
. 2020 Oct 29.
doi: 10.1038/s41551-020-00642-4. Online ahead of print.
Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates
Tiancheng Liu[SUP] 1 [/SUP], Jessica Hsiung[SUP] 1 [/SUP], Su Zhao[SUP] 1 [/SUP], Jessica Kost[SUP] 1 [/SUP], Deepika Sreedhar[SUP] 1 [/SUP], Carl V Hanson[SUP] 2 [/SUP], Kjerstie Olson[SUP] 3 [/SUP], Douglas Keare[SUP] 1 [/SUP], Shin Ting Chang[SUP] 1 [/SUP], Kevin P Bliden[SUP] 4 [/SUP], Paul A Gurbel[SUP] 4 [/SUP], Udaya S Tantry[SUP] 4 [/SUP], John Roche[SUP] 1 [/SUP], Cynthia Press[SUP] 3 [/SUP], John Boggs[SUP] 3 [/SUP], Jorge P Rodriguez-Soto[SUP] 3 [/SUP], Jose G Montoya[SUP] 5 [/SUP], Meijie Tang[SUP] 6 [/SUP], Hongjie Dai[SUP] 7 [/SUP]
Affiliations
- PMID: 33122853
- DOI: 10.1038/s41551-020-00642-4
Abstract
Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are essential for the control of the COVID-19 (coronavirus disease 2019) pandemic. Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobulin avidities against coronavirus antigens from SARS-CoV-2, SARS-CoV-1 and the common-cold viruses OC43, HKU1, NL63 and 229E. The antibody assay detected immunoglobulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the pandemic, including 73 that were positive for other viruses). We used the antibody-avidity assay to study antibody-maturation patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.